Blood-derived molecular signatures as biomarker panels for the early detection of colorectal cancer
- PMID: 32979165
- DOI: 10.1007/s11033-020-05838-0
Blood-derived molecular signatures as biomarker panels for the early detection of colorectal cancer
Abstract
Colorectal cancer (CRC) is one of the leading causes of tumor morbidity and mortality worldwide. Endoscopy is currently the main screening method, but the invasiveness and high cost hamper the application of endoscopy in asymptomatic patients with a risk of CRC and lead to a low diagnostic rate for early CRC. In recent years, the progress of transcriptomics, epigenetics, immunomics and metabolomics has greatly contributed to the identification of novel molecular markers for the noninvasive screening of CRC, and many molecules in various biological processes have been identified and evaluated for CRC detection. However, individual molecules always have insufficient diagnostic performance as biomarkers for the detection of CRC; therefore, a frequent strategy to overcome this deficiency is the use of molecule signatures as biomarker panels to improve the diagnostic power. Here, we reviewed the diagnostic performance of blood-derived molecular signatures (mRNAs, microRNAs, autoantibodies, and metabolites) as biomarker panels for CRC detection, particularly for early detection, and discussed their limitations and prospects.
Keywords: Biomarker panel; Colorectal cancer; Early diagnosis; Molecular signature.
Similar articles
-
Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer.Cancer Lett. 2014 May 1;346(2):178-87. doi: 10.1016/j.canlet.2014.01.007. Epub 2014 Jan 22. Cancer Lett. 2014. PMID: 24462820 Review.
-
Review of Blood-Based Colorectal Cancer Screening: How Far Are Circulating Cell-Free DNA Methylation Markers From Clinical Implementation?Clin Colorectal Cancer. 2018 Jun;17(2):e415-e433. doi: 10.1016/j.clcc.2018.02.012. Epub 2018 Mar 2. Clin Colorectal Cancer. 2018. PMID: 29678513 Review.
-
Multiplex quantitation of 270 plasma protein markers to identify a signature for early detection of colorectal cancer.Eur J Cancer. 2020 Mar;127:30-40. doi: 10.1016/j.ejca.2019.11.021. Epub 2020 Jan 21. Eur J Cancer. 2020. PMID: 31972396
-
Identification of microRNA-451a as a Novel Circulating Biomarker for Colorectal Cancer Diagnosis.Biomed Res Int. 2020 Aug 27;2020:5236236. doi: 10.1155/2020/5236236. eCollection 2020. Biomed Res Int. 2020. PMID: 32908896 Free PMC article.
-
Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals.J Transl Med. 2013 Oct 10;11:253. doi: 10.1186/1479-5876-11-253. J Transl Med. 2013. PMID: 24107468 Free PMC article.
Cited by
-
Autoantibody repertoire profiling in tissue and blood identifies colorectal cancer-specific biomarkers.Cancer Sci. 2024 Jan;115(1):83-93. doi: 10.1111/cas.16011. Epub 2023 Nov 20. Cancer Sci. 2024. PMID: 37985391 Free PMC article.
-
Multi-Omics Approaches in Colorectal Cancer Screening and Diagnosis, Recent Updates and Future Perspectives.Cancers (Basel). 2022 Nov 11;14(22):5545. doi: 10.3390/cancers14225545. Cancers (Basel). 2022. PMID: 36428637 Free PMC article. Review.
-
Evaluation of the diagnostic value of serum-based proteomics for colorectal cancer.World J Gastrointest Oncol. 2022 Aug 15;14(8):1562-1573. doi: 10.4251/wjgo.v14.i8.1562. World J Gastrointest Oncol. 2022. PMID: 36160749 Free PMC article.
-
Novel Diagnostic Biomarkers in Colorectal Cancer.Int J Mol Sci. 2022 Jan 13;23(2):852. doi: 10.3390/ijms23020852. Int J Mol Sci. 2022. PMID: 35055034 Free PMC article. Review.
-
CRISPR/Cas13-Based Platforms for a Potential Next-Generation Diagnosis of Colorectal Cancer through Exosomes Micro-RNA Detection: A Review.Cancers (Basel). 2021 Sep 16;13(18):4640. doi: 10.3390/cancers13184640. Cancers (Basel). 2021. PMID: 34572866 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical